Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Teva
Johnson and Johnson
QuintilesIMS
Fuji
AstraZeneca

Generated: March 23, 2019

DrugPatentWatch Database Preview

XURIDEN Drug Profile

« Back to Dashboard

When do Xuriden patents expire, and when can generic versions of Xuriden launch?

Xuriden is a drug marketed by Wellstat Therap and is included in one NDA. There is one patent protecting this drug.

This drug has one hundred and seventy-five patent family members in twenty-one countries.

The generic ingredient in XURIDEN is uridine triacetate. There are thirty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the uridine triacetate profile page.

Summary for XURIDEN
International Patents:175
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 56
Patent Applications: 42
Formulation / Manufacturing:see details
DailyMed Link:XURIDEN at DailyMed
Drug patent expirations by year for XURIDEN
Pharmacology for XURIDEN
Synonyms for XURIDEN
(2R,3R,4R,5R)-2-(ACETOXYMETHYL)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)TETRAHYDROFURAN-3,4-DIYL DIACETATE
[(2R,3R,4R,5R)-3,4-diacetoxy-5-(2,4-dioxopyrimidin-1-yl)tetrahydrofuran-2-yl]methyl acetate
[(2R,3R,4R,5R)-3,4-diacetyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl acetate
105T388
2 ,3 ,5 -Triacetyluridine
2',3',5'-Tri-O-acetyluridine
2',3',5'-Tri-O-acetyluridine, >=98%
293738-13-3
2WP61F175M
4105-38-8
AC1L2FGB
AK-73070
AKOS015964563
AN-158
ANW-29551
API0001026
AUFUWRKPQLGTGF-FMKGYKFTSA-N
AX8007900
CHEBI:90914
CHEMBL2107381
CTK3J5861
D09985
DB09144
EINECS 223-881-5
FT-0081134
J-700012
KSC495Q6D
MFCD00023795
MLS006009982
MolPort-005-940-324
PN 401
PN401
PubChem14176
RG 2133
SB18970
SCHEMBL871011
SMR004701034
Tri-O-acetyluridine
triacetyl uridine
Triacetyluridine
UNII-2WP61F175M
URI007
Uridine 2',3',5'-triacetate
Uridine triacetate
Uridine triacetate (USAN/INN)
Uridine triacetate [USAN:INN]
Uridine, 2',3',5'-triacetate
Vistogard
Vistonuridine
Xuriden (TN)
ZINC3843198

US Patents and Regulatory Information for XURIDEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wellstat Therap XURIDEN uridine triacetate GRANULE;ORAL 208169-001 Sep 4, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Wellstat Therap XURIDEN uridine triacetate GRANULE;ORAL 208169-001 Sep 4, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Wellstat Therap XURIDEN uridine triacetate GRANULE;ORAL 208169-001 Sep 4, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for XURIDEN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1849470 LUC00036 Luxembourg ➤ Sign Up PRODUCT NAME: TRIFLURIDINE COMBINEE AU TIPIRACIL OU UN SEL DE TIPIRACIL TEL QUE L'HYDROCHLORURE DE TIPIRACIL; AUTHORISATION NUMBER AND DATE: EU/1/16/1096 20160427
1849470 2017C/028 Belgium ➤ Sign Up PRODUCT NAME: LONSURF - TRIFLURIDINE/TIPIRACIL; AUTHORISATION NUMBER AND DATE: EU/1/16/1096 20160427
1849470 300889 Netherlands ➤ Sign Up PRODUCT NAME: TRIFLURIDINE IN COMBINATIE MET TIPIRACILHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160427
1849470 17C1028 France ➤ Sign Up PRODUCT NAME: TRIFLURIDINE/TIPIRACIL; REGISTRATION NO/DATE: EU/1/16/1096 20160427
1849470 1790063-0 Sweden ➤ Sign Up PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL HYDROCHLORIDE; REG. NO/DATE: EU/1/16/1096 20160427
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Merck
Teva
Cipla
Federal Trade Commission
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.